Page last updated: 2024-12-09

cyclouridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclouridine: structure given in third source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID806138
CHEMBL ID3251336
SCHEMBL ID1883172
MeSH IDM0050253

Synonyms (63)

Synonym
2,2'-anhydrouridine ,
cyclouridine
2,2'-anhydro-1(beta-d-arabinofuranosyl)uracil
2'-anhydro(1-.beta.-d-arabinofuranosyl)uracil
6h-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one, 2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-, (2r,3r,3as,9ar)-
(2r,3r,3as,9ar)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydrofuro[[?]:[?]]oxazolo[[?]]pyrimidin-6-one
2, 2'-anhydrouridine
2,2'-anhydro-(1-beta-d-arabinofuranosyl)uracil
DB04627
2,2'-anhydro(1-.beta.-d-arabinofuranosyl)uracil
nsc-157148
nsc157148
2,2'-o-cyclouridine
3736-77-4
o2,2'-cyclouridine
o2,2'-cyclouridine, 99%
inchi=1/c9h10n2o5/c12-3-4-6(14)7-8(15-4)11-2-1-5(13)10-9(11)16-7/h1-2,4,6-8,12,14h,3h2/t4-,6-,7+,8-/m1/s1
uugitdaswnoagg-ccxzuqqusa-
2,2'-cyclouridine
SCHEMBL1883172
o(2),2'-anhydrouridine
n9apx1aar4 ,
o2,2'-cyclouridine (van)
(2r-(2alpha,3beta,3abeta,9abeta))-2,3,3a,9a-tetrahydro-3-hydroxy-(hydroxymethyl)-6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one
2,2'-anhydro(1-beta-d-arabinofuranosyl)uracil
nsc 157148
6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one, 2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-, (2r-(2alpha,3beta,3abeta,9abeta))-
6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one, 2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-, stereoisomer (van)
unii-n9apx1aar4
einecs 223-107-6
2,2'-anhydro-1(b-d-arabinofuranosyl)uracil
AKOS015896944
bje ,
S4984
2,2'-anhydro-uridine
HG1148
CHEMBL3251336
J-700011
2,2'-anhydro-1($b-d-arabinofuranosyl)uracil
W-106545
(2r,3r,3as,9ar)-3-hydroxy-2-(hydroxymethyl)-2,3,3a,9a-tetrahydro-6h-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one
mfcd00004945
2,2'-anhydro-1(|?-d-arabinofuranosyl)uracil
CCG-252211
(2r,3r,3as,9ar)-2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-6h-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one
CS-W013029
anhydrouridine; 2,2'-anhydrouridine; cyclouridine
2,2'-anhydro uridine
UUGITDASWNOAGG-CCXZUQQUSA-N
2,2' anhydrouridine
2,2'anhydrouridine
HY-W012313
(2r,3r,3as,9ar)-2,3,3a,9a-tetrahydro-3-hydroxy-2-(hydroxymethyl)-6h-furo(2',3':4,5)oxazolo(3,2-a)pyrimidin-6-one
Q27095363
AS-15433
BRD-K46900527-001-01-4
2,2'-cyclouridine;o2,2'-cyclouridine
(2r,4r,5r,6s)-5-hydroxy-4-(hydroxymethyl)-3,7-dioxa-1,9-diazatricyclo[6.4.0.02,6]dodeca-8,11-dien-10-one
2 2-cyclouridine
NCGC00651741-01
DTXSID801315535
2,2 INVERTED EXCLAMATION MARK -O-CYCLOURIDINE
BP-58603
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1136033Inhibition of Herpesvirus 1 pyrimidine 2'-deoxyribonucleoside kinase by double reciprocal plot analysis in presence of thymidine1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Antiviral and antineoplastic activities of pyrimidine arabinosyl nucleosides and their 5'-amino derivatives.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's2 (20.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]